Abstracts may be submitted in the following topics:
| AS01 | PATHOGENESIS OF ATHEROSCLEROSIS |
| AS01.01 | Endothelial cell function and biology |
| AS01.02 | Smooth muscle cell biology |
| AS01.03 | Macrophages in lipid metabolism and atherosclerosis |
| AS01.04 | Inflammation, immunity and infection in atherosclerosis |
| AS01.05 | Extracellular matrix and calcification |
| AS01.06 | Vascular biology of the arterial wall |
| AS01.07 | Imaging |
| AS01.08 | Endothelial function |
| AS01.09 | Systems biology |
| AS01.10 | Clonal Haematopoiesis |
| AS01.11 | Plaque biology, vulnerable plaque |
| AS01.12 | Other |
| AS02 | LIPIDS AND LIPOPROTEINS |
| AS02.01 | Lp(a) |
| AS02.02 | TG rich lipoproteins metabolism and lipases |
| AS02.03 | HDL |
| AS02.04 | Lipoprotein receptors |
| AS02.05 | Lipidomics and metabolomics |
| AS02.06 | Cellular lipid metabolism and lipid droplets |
| AS02.07 | Lipid and lipoprotein metabolism |
| AS02.08 | Modified lipoproteins |
| AS02.09 | Liver metabolism and steatosis |
| AS02.10 | Adipose tissue biology and pathology |
| AS02.11 | Other |
| AS03 | DYSLIPIDEMIA AND RISK FACTORS |
| AS03.01 | Epidemiology of cardiovascular diseases and risk factors |
| AS03.02 | Epidemiology of dyslipidemias |
| AS03.03 | Diabetes, insulin sensitivity and resistance |
| AS03.04 | Adipose tissue homeostasis |
| AS03.05 | Inherited dyslipidemias |
| AS03.06 | Gender and cardiovascular risk |
| AS03.07 | Environmental risk factors |
| AS03.08 | Novel risk factors and biomarkers |
| AS03.09 | Epidemiology of socioeconomic and psychosocial risk factors |
| AS03.10 | Gut microbiome |
| AS03.11 | Gene editing technology |
| AS03.12 | Genomics, GWAS and population genetics; Mendelian randomization |
| AS03.13 | Epigenetics and microRNA |
| AS03.14 | Gene-Environment interactions |
| AS03.15 | Obesity |
| AS03.16 | Other |
| AS04 | CLINICAL VASCULAR DISEASE |
| AS04.01 | Coagulation and Thrombosis |
| AS04.02 | Endothelial dysfunction; Clinical assessment |
| AS04.03 | MAFLD, NASH and other ectopic lipid diseases |
| AS04.04 | Chronic kidney disease and nephropathies |
| AS04.05 | Diabetes; macro- and microangiopathies |
| AS04.06 | Obesity and weight-loss interventions |
| AS04.07 | Nutrition, nutraceuticals |
| AS04.08 | Weight-loss interventions |
| AS04.09 | Lipid-lowering therapies |
| AS04.10 | Anti-thrombotic therapies |
| AS04.11 | Anti-inflammatory therapies |
| AS04.12 | Prevention and treatment of cardiovasculardisease; miscellaneous |
| AS04.13 | New lipid lowering therapies |
| AS04.14 | SGTL2 inhibitors and cardiovascular diseases |
| AS04.15 | Artificial intelligence and big data |
| AS04.16 | Clinical imaging of atherosclerosis (invasive and non invasive) and ischaemia |
| AS04.17 | Artificial Intelegence |
| AS04.18 | Digital Health (wearables, remote monitoring, new technologies) |
| AS04.19 | Epidemiology, socioeconomic risk factors and health economics |
